Tokuyama Corporation FY2027 Q1 Earnings Report

Quick View

Executive Summary

In Q1 of the fiscal year ending March 2027, revenue increased, but higher SG&A expenses pressured earnings, resulting in declines at the operating and ordinary income levels. Meanwhile, extraordinary income, including gains on the sale of investment securities, boosted final profit. Revenue was ¥856.5B (+4.7% YoY), Operating Income was ¥60.8B (-22.9%), and Ordinary Income was ¥67.1B (-11.8%). Net Income attributable to owners of the parent was ¥52.0B (+6.0%), securing an increase in profit despite declines in Operating Income and Ordinary Income. The primary driver of revenue growth was the expansion of the Life Science Business (+61.5%), while the main factor behind the decline in Operating Income was an 18.9% increase in SG&A expenses.

Factors Affecting Performance

【Revenue】Revenue was ¥856.5B, an increase of +4.7% YoY. By segment, the Life Science Business grew significantly to ¥146.9B (+61.5%, 17.2% of total revenue), while Advanced Electronic Materials also contributed to revenue growth at ¥223.0B (+5.0%, 26.0% of total revenue). In contrast, Chemicals declined to ¥246.9B (-10.1%, 28.8% of total revenue), the Environmental Business decreased to ¥10.9B (-26.0%), and Cement was essentially flat at ¥160.5B (-0.2%). The primary driver of revenue growth was the expansion of the Life Science Business, while softening demand and pricing in Chemicals constrained overall growth.

【Profit and Loss】The gross margin improved to 35.0% from 34.2% in the previous year, an improvement of +0.8pt. However, the SG&A ratio rose to 27.9% from 24.6%, an increase of +3.3pt, causing the Operating Income margin to decline by -2.5pt to 7.1% (9.6% in the previous year). The increase in SG&A expenses (+18.9%) substantially exceeded the revenue growth rate (+4.7%), becoming a factor behind the decline in Operating Income. Non-operating income and expenses were net positive, including dividend income of ¥5.5B, equity in earnings of affiliates of ¥4.6B, and foreign exchange gains of ¥2.5B, narrowing the decline in Ordinary Income to ¥67.1B (-11.8%), compared with the decline in Operating Income. Extraordinary income of ¥7.0B, primarily comprising gains on the sale of investment securities of ¥6.4B, was recorded as a temporary factor. Profit before taxes was ¥73.2B (-4.6%), and after deducting income taxes and other taxes at an effective tax rate of 28.4%, Net Income attributable to owners of the parent was ¥52.0B (+6.0%). The overall picture was higher revenue but lower profit at the operating and ordinary income levels, while final profit increased due to the boost from extraordinary income; core profitability deteriorated from the previous year.

Segment Analysis

By segment, Advanced Electronic Materials (Operating Income of ¥31.3B, +10.8%, margin of 14.0%) and Life Science (Operating Income of ¥26.4B, +54.8%, margin of 18.0%) drove consolidated earnings as highly profitable segments. Cement remained stable at ¥25.5B (+1.4%, margin of 15.9%). In contrast, Chemicals fell sharply to ¥5.2B (-81.4%, margin of 2.1%), while the Environmental Business slipped into a loss of ¥-0.1B. The deterioration in profitability at both segments weighed on consolidated Operating Income. In the Life Science Business, the accounting treatment of goodwill related to Tokuyama Life Science Co., Ltd. (formerly JSR-01), acquired in October 2025, was finalized in Q1, reducing the goodwill balance. Differences in profit margins among segments have widened, and without an improvement in Chemicals’ profitability, the company’s overall business mix will become increasingly dependent on the two highly profitable segments.

Key Financial Metrics

【Profitability】The Operating Income margin was 7.1%, down -2.5pt from 9.6% in the previous year, while the Net Income margin (based on income attributable to owners of the parent) was 6.1%, essentially unchanged from 6.0% in the previous year. EPS was ¥72.34 (¥68.27 in the previous year, +6.0%).【Cash Flow Quality】Comprehensive income was ¥75.7B, exceeding Net Income attributable to owners of the parent of ¥52.0B by ¥22.2B. The primary factors were valuation difference on securities of +¥12.6B and foreign currency translation adjustments of +¥11.0B, indicating a significant contribution from valuation-related factors.【Investment Efficiency】ROE was 1.7%, with the low total asset turnover ratio acting as a bottleneck.【Financial Soundness】The Equity Ratio was 52.2%, essentially unchanged from 52.3% in the previous year. The current ratio of 173.8% and quick ratio of 149.4% indicate strong short-term liquidity resilience.

Cash Flow Analysis

Because cash flow statement data has not been disclosed, fund movements are analyzed based on changes in the balance sheet. Cash and deposits were ¥490.3B, an increase of +¥18.4B from ¥471.9B in the previous year. Trade receivables (the total of notes and accounts receivable) were ¥668.8B, down -¥89.9B from ¥758.7B in the previous year, while electronically recorded monetary claims increased by +¥17.4B, suggesting that some substitution among settlement methods may have progressed. Inventories were ¥302.8B, an increase of +¥39.8B (+15.1%) from ¥263.0B in the previous year, with notable accumulation of raw materials and work-in-process. Accounts payable were ¥495.4B, up +¥72.2B (+17.1%) from ¥423.2B in the previous year, indicating increased procurement activity. Construction in progress was ¥180.3B, down -¥120.1B (-40.0%) from ¥300.4B in the previous year, suggesting progress in transferring investment projects to property, plant and equipment. The increase in inventories and decrease in trade receivables offset each other, and changes in working capital are considered limited.

Quality of Earnings

The recurring source of earnings is core Operating Income of ¥60.8B, while extraordinary income of ¥7.0B, primarily comprising gains on the sale of investment securities of ¥6.4B, is a temporary factor and accounts for approximately 13.5% of Net Income attributable to owners of the parent of ¥52.0B. Non-operating income of ¥26.6B was only 3.1% of revenue and cannot be considered excessive dependence; however, foreign exchange gains of ¥2.5B are subject to fluctuations in market conditions. Comprehensive income was ¥75.7B, exceeding Net Income by ¥22.2B. Since the primary causes of this gap were increases in valuation difference on securities and foreign currency translation adjustments, this does not necessarily indicate an improvement in cash-generation capacity from business activities. Overall, core profitability declined from the previous year, and attention should be paid to the fact that the increase in final profit was supported by temporary extraordinary income and valuation-related factors in comprehensive income.

Earnings Forecast and Guidance

Q1 progress against the full-year plan was 21.9% for revenue (¥3,920.0B plan), 17.9% for Operating Income (¥340.0B plan), 19.7% for Ordinary Income (¥340.0B plan), and 20.0% for Net Income (¥260.0B plan). All metrics were below the 25% benchmark for simple progress, with the delay in Operating Income particularly pronounced. Against full-year expectations for revenue growth of +12.2%, the plan projects declines of -8.2% in Operating Income and -11.0% in Ordinary Income. Q1 results (revenue +4.7%, Operating Income -22.9%) show a larger decline in profit, making the pace of recovery toward the second half of the year critical to achieving the plan.

Shareholder Returns

The full-year dividend forecast is ¥60 per share, unchanged from the previous year’s actual dividend of ¥60. Based on forecast EPS of ¥361.38, the Payout Ratio is approximately 16.6%, remaining at a low level. Given the financial foundation of an Equity Ratio of 52.2% and a current ratio of 173.8%, the stability of funds available for dividends is considered favorable.

Risk Factors

1. Deterioration in Chemicals segment profitability: Against revenue of ¥246.9B (-10.1%), Operating Income fell sharply to ¥5.2B (-81.4%), with the margin declining to 2.1% (approximately 10.2% in the previous year). The contribution of Chemicals to consolidated Operating Income has contracted substantially, making the segment’s profitability trends a key point for monitoring consolidated performance.

2. Margin compression due to higher SG&A expenses: The SG&A ratio rose to 27.9% from 24.6% in the previous year, an increase of +3.3pt, while the growth rate (+18.9%) substantially exceeded the revenue growth rate (+4.7%). The improvement in the gross margin (+0.8pt) was offset by higher SG&A expenses, requiring assessment of whether the cost increase represents upfront investment or a structural increase in costs.

3. Dependence on temporary gains and valuation-related items: Extraordinary income of ¥7.0B (including gains on the sale of investment securities of ¥6.4B) accounts for approximately 13.5% of Net Income attributable to owners of the parent. The ¥22.2B gap between Comprehensive Income and Net Income is also primarily attributable to market-linked items such as valuation difference on securities and foreign currency translation adjustments.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Return

Both the company’s Operating Income margin and Net Income margin are below the industry median, placing profitability relatively low within the industry.

Growth and Capital Efficiency

The revenue growth rate is also below the industry median but exceeds the lower bound of the IQR, leaving growth at a mid-range level within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. The primary factor behind the decline in Operating Income was the 18.9% increase in SG&A expenses, substantially exceeding the revenue growth rate (+4.7%). The gross margin improved by +0.8pt, making whether the increase in expenses is temporary or structural a key consideration in assessing the future recovery of the Operating Income margin.

2. The segment mix is becoming increasingly dependent on the two highly profitable segments, Advanced Electronic Materials and Life Science (margins of 14.0% and 18.0%, respectively). The deterioration in Chemicals’ profitability (margin of 2.1%) is reflected in a shift in the composition of consolidated earnings.

3. Q1 progress against the full-year plan, including 17.9% for Operating Income, was below the standard benchmark of 25%. As the full-year plan itself anticipates higher revenue but lower profit, the pace of recovery toward the second half of the year will be an important factor in assessing achievement of the plan.

Theoretical Share Price (Reference Value)

This is a mechanically calculated reference range based solely on publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥3,941–¥4,179 at ±1% for the cost of equity, and ¥4,056–¥4,060 at ±0.1 for ω.

Note:

• Net assets as of the quarter-end are used (there is a timing gap relative to the full-year forecast).

(Calculation model: Residual Income Model / Interest Rate Reference Month: 2026-06 / This figure does not predict or guarantee the future share price)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting a professional as necessary.

---End of Report---